Not yet recruitingNo phase
To Evaluate The Efficacy And Safety Of Rivaroxaban In Combination With Aspirin Compared With Aspirin Monotherapy In Patients With Stable Coronary Artery Disease (CAD) and High Ischemic Risk
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Republican Specialized Scientific and Practical Medical Center of Cardiology
- Trial code
- NCT07928583
- Record updated
- 10 November 2026
- Original description
This study compares rivaroxaban plus aspirin with aspirin alone in patients with stable coronary artery disease at high ischemic risk. The aim is to evaluate whether the combination therapy better prevents cardiovascular events and to assess its safety.Read full original descriptionShow less
This study compares rivaroxaban plus aspirin with aspirin alone in patients with stable coronary artery disease at high ischemic risk. The aim is to evaluate whether the combination therapy better prevents cardiovascular events and to assess its safety.
Inclusion: Age 18 years or older; Stable coronary artery disease; High ischemic risk; Able to provide informed consent.
Exclusion: Active bleeding or high bleeding risk; Severe renal or hepatic impairment; Contraindication to rivaroxaban or aspirin; Pregnancy or breastfeeding.